jcp conference-coverage

Conference Coverage

Interview

Improving Patient Care Through AI Clinical Decision Support Tools

03/21/2023

James Hamrick, MD, MPH, discusses the ways in which incorporating AI into cancer care can improve the timeliness of care for patients, nudge providers to use novel therapies in practice, and reduce inequities in health care.

James Hamrick, MD, MPH,...

03/21/2023

Journal of Clinical Pathways

Interview

The Value of AI-Enabled Clinical Decision Support Tools in Clinical Pathways

03/20/2023

Rebecca Maniago, PharmD, BCOP, discusses the impact that AI-enabled clinical decision support will have on clinical pathways, as well as the ways in which technology is playing a large role in the current landscape of oncology care.

Rebecca Maniago, PharmD, BCOP,...

03/20/2023

Journal of Clinical Pathways

Videos

Analyzing the Cost-Effectiveness of Treatment Regimens in Metastatic Hormone-Sensitive Prostate Cancer

03/10/2023

Manish Kohli, MD, compared the cost-effectiveness of seven new treatments options for patients with metastatic hormone-sensitive prostate cancer, from the US public sector perspective.

Manish Kohli, MD, compared the...

03/10/2023

Journal of Clinical Pathways

News

Real-World Outcomes of EBRT Treatment for Patients With Localized Prostate Cancer

03/03/2023

Grace Taylor , MS, MA;

At the 2023 ASCO GU Cancers Symposium, Lawrence Karsh, MD, and colleagues presented data on real-world outcomes for using external beam radiation therapy to treat patients with high-risk localized prostate cancer (LPC) and...

At the 2023 ASCO GU Cancers...

03/03/2023

Journal of Clinical Pathways

News

Patient-Reported Quality of Life Analyses From the Phase 3 Momentum Study Compares Momelotiniob vs Danazol for the Treatment of Myelofibrosis

03/02/2023

Marta Rybczynski ;

A phase 3 study comparing danazol vs momelotinib for the treatment of myelofibrosis (MF) found that momelotinib demonstrated greater improvements in disease-related symptoms, physical function, and health-related quality of life among...

A phase 3 study comparing...

03/02/2023

Journal of Clinical Pathways

Conference Coverage

Exploring Use of Navitoclax in Conjunction With Ruxolitinib in Patients With MF Who are JAKi-Naïve

01/31/2023

Yvette C. Terrie , BS Pharm, RPh;

Findings from a recent study indicated that the combination of navitoclax and ruxolitinib for the treatment of primary or secondary MF among patients who were classified as JAKi-naïve provided promising and suggestive evidence of disease...

Findings from a recent study...

01/31/2023

Journal of Clinical Pathways

Conference Coverage

Machine Learning Model Beneficial in Predicting Overall Survival in Patients With Myelofibrosis

01/31/2023

Yvette C. Terrie , BS Pharm, RPh;

Findings from a recent study indicated that the use of a simple machine learning model known as the AIPSS-MF model was associated with an elevated rate of accuracy with regard to predicting OS in patients with primary and secondary MF,...

Findings from a recent study...

01/31/2023

Journal of Clinical Pathways

Conference Coverage

Researchers Present Status of PACIFICA Trial for Treatment of Primary or Secondary Myelofibrosis and Severe Thrombocytopenia

01/31/2023

Yvette C. Terrie , BS Pharm, RPh;

At the 64th ASH Annual Meeting, researchers provided information about the multinational, multicenter, randomized, controlled Phase III PACIFICA trial, which aims to gather data to validate the efficacy and safety of pacritinib vs the...

At the 64th ASH Annual Meeting,...

01/31/2023

Journal of Clinical Pathways

Conference Coverage

Cost-Effectiveness of Durvalumab Plus Gemcitabine and Cisplatin for Patients With Advanced Biliary Tract Cancer

01/30/2023

Grace Taylor , MS, MA;

In a cost analysis presented at the 2023 ASCO GI Cancers Symposium, researchers evaluated gemcitabine plus cisplatin with and without durvalumab among patients with advanced cholangiocarcinoma.

In a cost analysis presented at...

01/30/2023

Journal of Clinical Pathways

Conference Coverage

Zanubrutinib vs Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

12/13/2022

Katie Herman ;

Jennifer R Brown and colleagues presented PFS data from the ALPINE study which compared zanubrutinib with ibrutinib as treatment for R/R CLL/SLL at the 64th ASH Annual Meeting and Exposition.

Jennifer R Brown and colleagues...

12/13/2022

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

2024 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Update: Impact on NSCLC Landscape

11/15/2024

The updated 2024 NCCN Guidelines® recommend broad genomic testing and the need for multidisciplinary care to accurately diagnose and treat non-small cell lung cancer. View this special report to learn more.

The updated 2024 NCCN...

11/15/2024

Journal of Clinical Pathways

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Conference Coverage

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products